Cathie Wood
FATE icon

Cathie Wood’s Fate Therapeutics FATE Stock Holding History

Cathie Wood’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-4,214,863
Closed -$42.5M – 225
2022
Q4 		$42.5M Sell
4,214,863
-7,440,970
-64% -$140M 0.37% 42
2022
Q3 		$261M Buy
11,655,833
+182,178
+2% +$5.26M 1.82% 19
2022
Q2 		$265M Buy
11,473,655
+485,473
+4% +$13.4M 1.57% 20
2022
Q1 		$426M Buy
10,988,182
+676,015
+7% +$26.2M 1.78% 17
2021
Q4 		$603M Sell
10,312,167
-590,091
-5% -$33.4M 1.82% 18
2021
Q3 		$646M Buy
10,902,258
+3,419,156
+46% +$268M 1.55% 20
2021
Q2 		$649M Buy
7,483,102
+928,556
+14% +$74.8M 1.21% 26
2021
Q1 		$540M Buy
6,554,546
+3,652,846
+126% +$350M 1.07% 28
2020
Q4 		$264M Buy
2,901,700
+1,461,730
+102% +$90.8M 0.7% 41
2020
Q3 		$57.6M Buy
1,439,970
+420,140
+41% +$14.7M 0.34% 53
2020
Q2 		$35M Buy
1,019,830
+464,748
+84% +$13.9M 0.38% 45
2020
Q1 		$12.3M Buy
555,082
+123,954
+29% +$3.13M 0.31% 53
2019
Q4 		$8.44M Buy
431,128
+92,089
+27% +$1.46M 0.21% 60
2019
Q3 		$5.26M Buy
339,039
+116,975
+53% +$2.24M 0.11% 71
2019
Q2 		$4.51M Buy
+222,064
New +$4M 0.11% 75

Other funds holding FATE

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Cathie Wood's FATE Position: Q1 2023 in Review

Cathie Wood sold out of Fate Therapeutics (FATE) in Q1 2023, closing a stake of 4,214,863 shares — an estimated $42.5M sold.

Cathie Wood first reported a position in FATE in Q2 2019 and held it in 15 quarters. The position peaked at $649M in Q2 2021. 181 funds tracked by Wall St. Rank hold FATE as of Q1 2023.

  • Cathie Wood reported no remaining Fate Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Cathie Wood sold 4,214,863 Fate Therapeutics shares in Q1 2023, an estimated $42.5M.
  • Cathie Wood first reported a position in Fate Therapeutics in Q2 2019 and held it in 15 quarters.
  • Cathie Wood's Fate Therapeutics position peaked at $649M in Q2 2021.
  • 181 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2023.

Based on ARK Investment Management's 13F filing for Q1 2023, filed 17 Apr 2023.